Tag: Pexa-Vec

August 1, 2017 Off

Transgene testing Opdivo with Pexa-Vec to treat HCC – first patient treated

By Dino Mustafić

Transgene has treated the first patient in a Phase 1/2 clinical trial for the combination of Pexa-Vec with Opdivo as a first-line treatment of advanced hepatocellular carcinoma (HCC). The trial will assess the safety and tolerability as well as the anti-tumor activity and efficacy of this immunotherapy combination regimen in up to 36 patients (NCT03071094).  This tumour accounts for approximately 75% of liver cancers.